In ANA-high or ENA-positive patients, especially those with established CLE or SLE, this IFN-skewing effect may increase risk and highlights the importance of considering ANA/ENA profiles when planning light-based therapy [20,38]. This evidence concerns the gene BTG3 and systemic lupus erythematosus.